BackKKALSHI

What will the FDA's decision be on Tozorakimab by AstraZeneca on or before March 31, 2027?

Yes 50.0%

Vol0 contracts

SnapshotOct 29, 2026, 12:00 AM UTC

Yes 50.0%

TradeTrade on Kalshi

Event

MarketKALSHIactive

MarketKALSHIactiveHealth

What will the FDA's decision be on Tozorakimab by AstraZeneca on or before March 31, 2027?

Part of: FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

YesYes Price

50.0¢

VolTotal Volume

0 contracts

Outcomes

Ends

Apr 8, 2027, 2:00 PM UTC

Trade on Kalshi

What will the FDA's decision be on Tozorakimab by AstraZeneca on or before March 31, 2027?

Yes

50.0¢

Vol

0 contracts

Outcomes

Trade

Yes50.0¢

No50.0¢

Outcome

Yes quoted price: 50.0%. Snapshot Oct 29, 2026, 12:00 AM UTC. History may have a different observation time.

Price History

What will the FDA's decision be on Tozorakimab by AstraZeneca on or before March 31, 2027? · Yes

No historical data available

Price history will appear here when available

Rules and settlement

Listed close: Apr 8, 2027, 2:00 PM UTC. Settlement follows the provider's contract terms and may occur later.

If the FDA's decision on Tozorakimab by AstraZeneca on or before March 31, 2027 is a full approval or an accelerated approval, the market resolves to Yes. Secondary rules: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Early close condition: This market will close early if the FDA issues a decision on Tozorakimab before Apr 1, 2027

Read this contract on Kalshi

Resolution Info